Evidence map›Paper›PMID 35624975›Full record

ArticleBrain sciences2022

Sex Differences in Plasma Lysophosphatidic Acid Species in Patients with Alcohol and Cocaine Use Disorders.

María Flores-López, Nuria García-Marchena, Pedro Araos, Nerea Requena-Ocaña, Oscar Porras-Perales, Sandra Torres-Galván, Juan Suarez, Nieves Pizarro, Rafael de la Torre, Gabriel Rubio and 4 more

Open access · goldAbstract read
In one paragraph

Article in Brain sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 6 institutions in 1 country.

María Flores-LópezInstituto de Investigación Biomédica de Málaga-IBIMA, 29590 Málaga, Spain.ORCID 0000-0003-3489-1465
Nuria García-MarchenaInstituto de Investigación Biomédica de Málaga-IBIMA, 29590 Málaga, Spain.
Pedro AraosInstituto de Investigación Biomédica de Málaga-IBIMA, 29590 Málaga, Spain.ORCID 0000-0001-5172-8796
Nerea Requena-OcañaInstituto de Investigación Biomédica de Málaga-IBIMA, 29590 Málaga, Spain.
Oscar Porras-PeralesInstituto de Investigación Biomédica de Málaga-IBIMA, 29590 Málaga, Spain.
Sandra Torres-GalvánInstituto de Investigación Biomédica de Málaga-IBIMA, 29590 Málaga, Spain.
Juan SuarezInstituto de Investigación Biomédica de Málaga-IBIMA, 29590 Málaga, Spain.ORCID 0000-0001-5254-9802
Nieves PizarroGrup de Recerca en Farmacologia Integrada i Neurociència de Sistemes, Programa de Recerca en Neurociéncia, Institut Hospital del Mar d'Investigacions Mèdiques-IMIM, 08003 Barcelona, Spain.ORCID 0000-0003-2671-7184
Rafael de la TorreGrup de Recerca en Farmacologia Integrada i Neurociència de Sistemes, Programa de Recerca en Neurociéncia, Institut Hospital del Mar d'Investigacions Mèdiques-IMIM, 08003 Barcelona, Spain.ORCID 0000-0002-6765-1866
Gabriel RubioServicio de Psiquiatría, Hospital Universitario 12 de Octubre, 28041 Madrid, Spain.
Juan Jesús Ruiz-RuizCentro Provincial de Drogodependencias de Málaga, Diputación Provincial de Málaga, 29010 Málaga, Spain.
Fernando Rodríguez de FonsecaInstituto de Investigación Biomédica de Málaga-IBIMA, 29590 Málaga, Spain.ORCID 0000-0002-4516-5795
Antonia SerranoInstituto de Investigación Biomédica de Málaga-IBIMA, 29590 Málaga, Spain.
Francisco Javier Pavón-MorónInstituto de Investigación Biomédica de Málaga-IBIMA, 29590 Málaga, Spain.ORCID 0000-0002-5256-8904
Hospital Regional Universitario de Málaga · ESInstituto de Salud Carlos III · ESHospital del Mar Research Institute · ESHospital Universitario 12 De Octubre · ESInstituto de Investigación Biomédica de Málaga · ESUniversidad Complutense de Madrid · ES

Funding

Consejeria de Economia, Conocimiento, Empresas y Universidad UMA 181-FEDERJA-059Consejería de Salud y Familias PI-0140-2018Instituto de Salud Carlos III FI18/00249; CD19/00019; CPII19/00022; and CPII19/00031Instituto de Salud Carlos III PI19/00886; PI19/01577; PI20/01399Instituto de Salud Carlos III RD16/0017/0001Instituto de Salud Carlos III RD21/0009/0003Ministry of Health PND2017/043; PND2018/033; PND2018/044 and PND2019/040
6 · The paper itself

Abstract

Preclinical evidence suggests a main role of lysophosphatidic acid (LPA) signaling in drug addiction. Recently, we reported alterations in the plasma concentrations of LPA species in patients with alcohol use disorder (AUD). As there are sex differences in drug addiction, the main aim of the present study was to investigate whether relevant LPA species (16:0-LPA, 18:0-LPA, 18:1-LPA, 18:2-LPA and 20:4-LPA) were associated with sex and/or substance use disorder (SUD). This exploratory study was conducted in 214 abstinent patients with lifetime SUD, and 91 healthy control subjects. The SUD group was divided according to the diagnosis of AUD and/or cocaine use disorder (CUD). Participants were clinically assessed, and plasma samples were collected to determine LPA species and total LPA. We found that LPA concentrations were significantly affected by sex, and women showed higher concentrations than men. In addition, there were significantly lower 16:0-LPA, 18:2-LPA and total LPA concentrations in patients with SUD than in controls. Namely, patients with CUD and AUD + CUD showed lower LPA concentrations than controls or patients with AUD. In conclusion, our data suggest that LPA species could be potential biomarkers for SUD in women and men, which could contribute to a better stratification of these patients in treatment programs.

Indexed as

alcoholbiomarkercocainelysophosphatidic acidsexsubstance use disorder

Identifiers

PMID35624975
PMCPMC9139721
OpenAlexW4225248801

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.